Novozymes Biopharma signs agreement with GE Healthcare to produce and sell Protein A
Novozymes Biopharma UK, part of Novozymes of Sweden, a leader in bioinnovation, has signed an agreement with GE Healthcare Life Sciences to produce native, animal-free protein A using GE Healthcare technology.
Novozymes Biopharma UK, part of Novozymes of Sweden, a leader in bioinnovation, has signed an agreement with GE Healthcare Life Sciences to produce native, animal-free protein A using GE Healthcare technology.
Novozymes Biopharma's protein A, which is commercially available, is targeted at producers of chromatography media.
Novozymes Biopharma is producing the protein in Sweden. It is the active component in chromatography media used in the production of antibodies. The protein can then be used to purify antibodies in drug production and bio-chemical analysis.
The ability of protein A to bind to antibodies has been used successfully at industrial scale for several years to produce monoclonal antibodies that are used as drugs in the treatment of illnesses such as arthritis and cancer.
Caspar Foghsgaard, strategic product director at Novozymes Biopharma, said: "We are already filling up our stock capacities with raw materials and the final product to deal with the demand for this exciting product."
